Abstract | INTRODUCTION: AREAS COVERED: This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity as well as the emerging role of newer purine and pyrimidine nucleoside analogs potentially active in lymphoid and myeloid malignancies. A literature review was conducted from the MEDLINE database PubMed for articles in English. Publications from 2000 to October 2010 were scrutinized. The search terms used were clofarabine, nelarabine, forodesine, 8-chloroadenosine, LMP-420, azacitidine, decitabine, sapacitabine, troxacitabine, thiarabine and zebularine in conjunction with hematologic malignancies, leukemia and lymphoma. Conference proceedings from the previous 5 years of the American Society of Hematology, European Hematology Association, and American Society of Clinical Oncology were searched manually. Additional relevant publications were obtained by reviewing the references from the chosen articles. EXPERT OPINION:
|
Authors | Tadeusz Robak |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 20
Issue 3
Pg. 343-59
(Mar 2011)
ISSN: 1744-7658 [Electronic] England |
PMID | 21320002
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
|
Topics |
- Animals
- Clinical Trials as Topic
- Hematologic Neoplasms
(drug therapy)
- Humans
- Nucleosides
(therapeutic use)
|